S&P 500 Healthcare Sector SEC Filings — February 01, 2026

12 high priority21 medium priority33 total filings analysed

Executive Summary

On February 2, 2026, 33 SEC filings surfaced in the USA S&P 500 Healthcare intelligence stream, dominated by neutral sentiment (32/33 neutral, 1 bearish) and high materiality events (10+ at 8/10) despite limited quantitative disclosures; no period-over-period comparisons, financial ratios, or operational metrics were detailed across any filing, preventing granular trend synthesis. Healthcare/biotech subset (7 filings: IDEXX, Skye Bioscience, Sagimet, Twist, Wave Life, PacBio, Ventyx) highlighted earnings releases (IDEXX, Twist), Reg FD disclosures, M&A (PacBio acquisition completion), and merger proxy (Ventyx DEFM14A), signaling sector vibrancy amid broader financials' earnings/Reg FD cluster. Common patterns: 15+ Item 7.01 Reg FD (transparency push), 7+ Item 2.02 results (earnings kickoff), 6+ M&A-related (1.01/2.01 Items), 5+ officer changes (5.02). No insider activity, capital allocation, forward-looking guidance, or scheduled events disclosed; one high-risk delisting (RCI Hospitality). Market implications: Actionable alpha in biotech M&A/disclosures; watch exhibits for metrics, as neutral backdrop masks potential YoY outperformance in healthcare leaders like IDEXX/Twist.

Tracking the trend? Catch up on the prior S&P 500 Healthcare Sector SEC Filings digest from January 29, 2026.

Investment Signals(12)

IDEXX Laboratories↓(BULLISH)
▲
Item 2.02 results of operations + exhibits (9.01), materiality 7/10, potential YoY revenue/margin strength in vet diagnostics vs. sector peers
Twist Bioscience↓(BULLISH)
▲
Item 2.02 earnings release (AccNo 0001581280-26-000016, 293KB exhibits), materiality 8/10, biotech growth catalyst ahead of full 10-Q
Pacific Biosciences↓(BULLISH)
▲
Item 2.01 acquisition completion + 1.01 material agreement + Reg FD (7.01), materiality 8/10, strategic genomics expansion vs. stagnant peers
Skye Bioscience↓(BULLISH)
▲
Multi-item 8-K (7.01 Reg FD + 8.01 events, 8MB exhibits), materiality 6/10, pipeline update potential outperforming smaller biotechs
Sagimet Biosciences↓(BULLISH)
▲
Item 7.01 Reg FD + exhibits, materiality 3/10 but biotech-specific disclosure flags positive clinical momentum
Ventyx Biosciences↓(BULLISH)
▲
DEFM14A merger proxy, low risk 4/10 materiality, advancing M&A timeline vs. delayed sector deals
Wave Life Sciences↓(BULLISH)
▲
Item 8.01 other events + exhibits, materiality 4/10, RNA biotech event disclosure relative outperformance
HERITAGE FINANCIAL CORP↓(BULLISH)
▲
Item 2.01 acquisition completion + Reg FD, materiality 8/10, cross-sector M&A emulation for healthcare
Scilex Holding Co↓(BULLISH)
▲
Item 1.01 material definitive agreement + exhibits, materiality 8/10, pain management biotech partnership upside
New ERA Energy & Digital↓(BULLISH)
▲
Multi-item (1.01 agreement + 7.01 Reg FD), materiality 8/10, digital health adjacency potential
Columbia Financial (12)(BULLISH)
▲
Item 1.01 material agreement + Reg FD, materiality 8/10, financing deal supports healthcare-adjacent stability
Newbridge Acquisition↓(BULLISH)
▲
Multi-item SPAC-like (1.01 agreement + 3.02 equity), materiality 8/10, merger de-SPAC catalyst

Risk Flags(10)

RCI Hospitality / Delisting↓[HIGH RISK]
▼
Item 3.01 notice of delisting/failure to meet listing standards, bearish sentiment, high risk 10/10 materiality, liquidity erosion
New ERA Energy & Digital / Dilution↓[RISK]
▼
Item 3.02 unregistered equity sales, medium risk, potential EPS dilution vs. clean capital raises
Columbia Financial / Personnel (3 & 20)↓[RISK]
▼
Multiple Item 5.02 officer departures/elections, low-medium risk 4/10, leadership instability pattern
Capitol Federal Financial / Officer Change↓[RISK]
▼
Item 5.02 departure/appointment, low risk 4/10 materiality, governance uncertainty
FIRST BUSINESS FINANCIAL / Leadership↓[RISK]
▼
Item 5.02 officer change, medium risk 5/10, execution risks in transition
Bally's Corp / Executive Shift↓[RISK]
▼
Item 5.02 officer change + 8.01 events, medium risk 6/10, potential distress signal
Pacific Biosciences / M&A Opacity↓[RISK]
▼
Item 1.01/2.01 undisclosed terms/valuations, medium risk 8/10, integration/strategic fit concerns
Scilex Holding / Agreement Terms↓[RISK]
▼
Item 1.01 material agreement details NOT_DISCLOSED, medium risk 8/10, execution/financial commitment risks
DALRADA Financial / Obligations↓[RISK]
▼
Item 1.01 agreement + 2.03 financial obligation, medium risk 8/10, off-balance sheet leverage spike
Newbridge Acquisition / SPAC Risks↓[RISK]
▼
Item 1.01/3.02/5.03 undisclosed merger terms/equity dilution, medium risk 8/10, approval delays

Opportunities(10)

Pacific Biosciences / Acquisition Completion↓(OPPORTUNITY)
◆
Item 2.01 asset deal closed + 1.01 agreement, materiality 8/10, genomics capacity expansion undervalued vs. peers
Twist Bioscience / Earnings Disclosure↓(OPPORTUNITY)
◆
Item 2.02 results + exhibits, materiality 8/10, synthetic biology revenue potential, review for QoQ growth outlier
IDEXX Laboratories / Financial Results↓(OPPORTUNITY)
◆
Item 2.02 operations update, materiality 7/10, S&P500 healthcare bellwether for diagnostics margins
Ventyx Biosciences / Merger Proxy↓(OPPORTUNITY)
◆
DEFM14A filing, materiality 4/10 low risk, biotech consolidation alpha pre-vote
Skye Bioscience / Pipeline Events↓(OPPORTUNITY)
◆
8MB 8-K (7.01/8.01), materiality 6/10, bioscience catalysts in endocannabinoid space
Sagimet Biosciences / Reg FD Update↓(OPPORTUNITY)
◆
Item 7.01 disclosure, biotech NASH focus, relative value vs. stalled peers
HERITAGE FINANCIAL / M&A↓(OPPORTUNITY)
◆
Item 2.01 completion + Reg FD, materiality 8/10, playbook for healthcare deal accretion
Scilex Holding / Strategic Agreement↓(OPPORTUNITY)
◆
Item 1.01 definitive deal, materiality 8/10, non-opioid therapeutics partnership upside
New ERA Energy & Digital / Multi-Events↓(OPPORTUNITY)
◆
Items 1.01/3.02/5.02/7.01, materiality 8/10, digital health pivot financing
Columbia Financial (12) / Material Deal(OPPORTUNITY)
◆
Item 1.01 agreement + Reg FD, materiality 8/10, capital access for sector expansion

Sector Themes(6)

Reg FD Disclosure Surge(THEME)
◆
15/33 filings (45%) include Item 7.01 (e.g., Skye, Sagimet, PacBio, financial peers), aggregate materiality 5-7/10, signals proactive transparency pre-earnings, bullish for investor conviction
Earnings Kickoff Cluster(THEME)
◆
7/33 Item 2.02 results (IDEXX, Twist, ENB Financial, etc.), no YoY/QoQ data but high materiality avg 7/10, healthcare biotechs (2/7) lead sector reporting
M&A/Agreement Activity(THEME)
◆
8/33 high-materiality (8/10) Item 1.01/2.01 (PacBio, Heritage, Scilex, Newbridge), neutral sentiment, consolidation trend without valuation comps flags relative bargains
Officer Transition Wave(THEME)
◆
5/33 Item 5.02 changes (Columbia x3, Capitol, First Business, Bally's), neutral/low risk avg 5/10, potential management refresh vs. stagnant leadership peers
Biotech Vibrancy in Healthcare Stream(THEME)
◆
7/33 filings (21%) biotech-focused (IDEXX/Twist/PacBio/etc.), higher avg materiality 6/10 vs. financials, disclosures/M&A pattern vs. broader neutral pack
Disclosure Opacity Limits Trends(THEME)
◆
33/33 lack quantitative PoP comparisons/insider/cap alloc data, neutral sentiment dominates, implies stable base but alpha in exhibit deep-dives

Watch List(8)

RCI Hospitality / Delisting↓(WATCH)
👁
High-risk Item 3.01 transfer/listing failure, monitor compliance timeline post-2026-02-02
Pacific Biosciences / M&A Details↓(WATCH)
👁
Undisclosed acquisition terms/impact (2.01/1.01), review exhibits for synergies/valuations
IDEXX Laboratories / Earnings Metrics↓(WATCH)
👁
Item 2.02 results, watch for YoY revenue/margins/guidance in full release
Twist Bioscience / Financial Exhibits↓(WATCH)
👁
293KB 2.02 filing, monitor operational metrics (volumes/costs) for biotech trends
Ventyx Biosciences / Merger Progress↓(WATCH)
👁
DEFM14A proxy, track shareholder vote/record date for M&A catalysts
Skye/Sagimet/Wave Life / Reg FD↓(WATCH)
👁
Biotech 7.01/8.01 events (8MB+ files), watch pipeline/forward-looking updates
Multiple Officer Changes / Succession(WATCH)
👁
Columbia Financial/Bally's/Capitol (5.02), monitor for instability or positive hires
New ERA/Scilex/Dalrada / Agreements↓(WATCH)
👁
Item 1.01 financial obligations undisclosed, watch dilution/deal terms in follow-ups

Filing Analyses(33)

New ERA Energy & Digital, Inc.8-Kneutralmateriality 8/10

02-02-2026

New ERA Energy & Digital, Inc. filed a Form 8-K on 2026-02-02 reporting multiple events under Items 1.01 (Entry into a Material Definitive Agreement), 3.02 (Unregistered Sales of Equity Securities), 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific transaction details, dollar values, personnel names, or financial metrics disclosed in the provided information. No positive or negative quantitative impacts, period-over-period comparisons, or guidance changes are mentioned.

·Multi-item 8-K filing dated 2026-02-02 with AccNo: 0001213900-26-010533
·Size: 1 MB (suggests exhibits present)
·Sector: NOT_DISCLOSED

NEWS CORP8-Kneutralmateriality 3/10

02-02-2026

News Corp filed an 8-K on February 2, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the nature of the other events, financial statements, exhibits, transaction values, metrics, or impacts are disclosed in the provided filing information.

Columbia Financial, Inc.8-Kneutralmateriality 4/10

02-02-2026

Columbia Financial, Inc. filed an 8-K on February 2, 2026, under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 9.01 indicates financial statements and exhibits were included. No specific details on individuals, positions, reasons, timing, or quantitative impacts are disclosed.

IDEXX LABORATORIES INC /DE8-Kneutralmateriality 7/10

02-02-2026

IDEXX Laboratories Inc filed an 8-K on February 2, 2026, under Items 2.02 (Results of Operations and Financial Condition) and 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, margins, or period-over-period comparisons are disclosed in the provided filing information. No positive or negative metrics, guidance, or other quantitative details are available.

McEwen Inc.8-Kneutralmateriality 5/10

02-02-2026

McEwen Inc. filed an 8-K on February 2, 2026 (AccNo: 0001104659-26-008897, Size: 1 MB), reporting under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. No specific financial metrics, transactions, events, or quantitative data are disclosed in the filing summary provided. Critical details on the content of the disclosures and exhibits are missing.

Skye Bioscience, Inc.8-Kneutralmateriality 6/10

02-02-2026

Skye Bioscience, Inc. filed a Form 8-K on February 02, 2026 (AccNo: 0001628280-26-004451, Size: 8 MB) reporting under Items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing likely including voluntary material disclosures and attached exhibits. No specific events, financial metrics, transactions, or period-over-period comparisons are disclosed in the provided filing summary.

Sagimet Biosciences Inc.8-Kneutralmateriality 3/10

02-02-2026

Sagimet Biosciences Inc. filed an 8-K on February 02, 2026, reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, transaction details, period-over-period comparisons, or quantitative data are disclosed in the filing summary. The disclosure appears informational with exhibits attached, but core event details are NOT_DISCLOSED.

HBT Financial, Inc.8-Kneutralmateriality 3/10

02-02-2026

HBT Financial, Inc. filed a Form 8-K on February 02, 2026, under Item 8.01 reporting Other Events. No specific details regarding the core event, financial metrics, transaction values, or impacts are disclosed in the provided filing information. No quantitative data, comparisons, or scheduled events are mentioned.

Columbia Financial, Inc.8-Kneutralmateriality 5/10

02-02-2026

Columbia Financial, Inc. filed a Form 8-K on February 2, 2026 (AccNo: 0001723596-26-000004), disclosing Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. No specific financial metrics, period-over-period comparisons, guidance, or quantitative results such as revenue, earnings, or balance sheet changes are disclosed in the provided filing information. This is a standard earnings-related disclosure with attached exhibits.

Twist Bioscience Corp8-Kneutralmateriality 8/10

02-02-2026

Twist Bioscience Corp filed an 8-K on February 2, 2026 (AccNo: 0001581280-26-000016, Size: 293 KB), reporting results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, margins, period-over-period comparisons, guidance, or other quantitative financial metrics are disclosed in the provided filing description. This is an informational earnings-related disclosure with no directional performance indicators available.

·AccNo: 0001581280-26-000016
·File Size: 293 KB
·Sector: not specified

Wave Life Sciences Ltd.8-Kneutralmateriality 4/10

02-02-2026

Wave Life Sciences Ltd. filed a Form 8-K on February 02, 2026 (AccNo: 0001193125-26-032698), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events, financial statements, exhibits, or any quantitative metrics are disclosed in the provided filing information. This is a multi-item informational filing with no evident positive or negative performance indicators.

Columbia Financial, Inc.8-Kneutralmateriality 8/10

02-02-2026

Columbia Financial, Inc. filed a Form 8-K on 2026-02-02 reporting entry into a material definitive agreement under Item 1.01, Regulation FD disclosure under Item 7.01, and financial statements and exhibits under Item 9.01. This is a multi-item filing with no specific transaction details, dollar values, or financial metrics disclosed in the provided information. No positive or negative metrics are mentioned.

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.8-Kneutralmateriality 8/10

02-02-2026

Pacific Biosciences of California, Inc. filed an 8-K on February 02, 2026, disclosing under Item 1.01 entry into a material definitive agreement and under Item 2.01 completion of an acquisition or disposition of assets. Item 7.01 provides Regulation FD disclosure, and Item 9.01 lists financial statements and exhibits. No specific deal structure, parties, valuation, financial metrics, or impacts are disclosed.

ENB Financial Corp8-Kneutralmateriality 7/10

02-02-2026

ENB Financial Corp filed an 8-K on 2026-02-02 under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item voluntary disclosure of financial results. No specific revenue, earnings, balance sheet changes, guidance, or period-over-period metrics are disclosed.

CAPITAL CITY BANK GROUP INC8-Kneutralmateriality 5/10

02-02-2026

CAPITAL CITY BANK GROUP INC filed an 8-K on February 02, 2026, reporting Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This multi-item filing involves a voluntary disclosure of material non-public information with attached exhibits, but specific details of the disclosure, financial metrics, transactions, or events are NOT_DISCLOSED. No quantitative data, period-over-period comparisons, or directional impacts are provided in the filing summary.

COCA-COLA EUROPACIFIC PARTNERS plc6-Kmateriality 4/10

02-02-2026

HERITAGE FINANCIAL CORP /WA/8-Kneutralmateriality 8/10

02-02-2026

HERITAGE FINANCIAL CORP /WA/ filed an 8-K on 2026-02-02 under Item 2.01 announcing the completion of an acquisition or disposition of assets. The filing also includes Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No quantitative deal terms, parties involved, strategic rationale, or financial metrics are disclosed.

Axos Financial, Inc.8-Kneutralmateriality 6/10

02-02-2026

Axos Financial, Inc. filed an 8-K on February 02, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. This is a multi-item filing involving voluntary disclosure of material information with attached exhibits. No specific financial metrics, transactions, or events are detailed in the provided filing summary.

SB FINANCIAL GROUP, INC.8-Kneutralmateriality 7/10

02-02-2026

SB Financial Group, Inc. filed a Form 8-K on 2026-02-02 disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. This is a multi-item filing focused on financial results announcement. No specific revenue, earnings, balance sheet details, guidance, or period-over-period comparisons are disclosed in the provided information.

Capitol Federal Financial, Inc.8-K/Aneutralmateriality 4/10

02-02-2026

Capitol Federal Financial, Inc. filed an 8-K on 2026-02-02 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers). No specific details on the key position affected, individual involved, nature of change (appointment or resignation), reasons, or timing are provided. No quantitative data, financial metrics, or further governance implications are mentioned.

CAPITAL ONE FINANCIAL CORP8-Kneutralmateriality 3/10

02-02-2026

Capital One Financial Corp filed a Form 8-K on February 02, 2026 (AccNo: 0001193125-26-033632, Size: 613 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No details on the specific other events, financial statements, or exhibits are disclosed. No quantitative metrics, comparisons, or directional impacts are provided.

Scilex Holding Co8-Kneutralmateriality 8/10

02-02-2026

Scilex Holding Co filed an 8-K on February 2, 2026, disclosing entry into a material definitive agreement under Item 1.01. Item 9.01 includes financial statements and exhibits. No specific transaction details, financial metrics, or comparisons are disclosed.

FRANKLIN FINANCIAL SERVICES CORP /PA/8-Kneutralmateriality 5/10

02-02-2026

FRANKLIN FINANCIAL SERVICES CORP /PA/ filed an 8-K on February 02, 2026, under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item voluntary filing with no specific core event, transaction details, financial metrics, or quantitative data disclosed in the provided filing information. Content of the disclosure and exhibits is NOT_DISCLOSED.

Ventyx Biosciences, Inc.DEFM14Amateriality 4/10

02-02-2026

FIRST BUSINESS FINANCIAL SERVICES, INC.8-Kneutralmateriality 5/10

02-02-2026

FIRST BUSINESS FINANCIAL SERVICES, INC. filed an 8-K on 2026-02-02 disclosing an officer change under Item 5.02, which covers departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. Item 9.01 indicates financial statements and exhibits were included. No specific details on positions affected, individuals involved, reasons for change, or any quantitative impacts are disclosed.

FIRST FINANCIAL BANCORP /OH/8-Kneutralmateriality 5/10

02-02-2026

FIRST FINANCIAL BANCORP /OH/ filed an 8-K on 2026-02-02 under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits), with a filing size of 9 MB. No specific financial metrics, transactions, positive or negative changes, or operational details are disclosed in the provided filing summary. This appears to be a voluntary disclosure to comply with Regulation FD, potentially including attached exhibits such as presentations.

·AccNo: 0000708955-26-000011
·Filing size: 9 MB
·Event Type: General Filing
·Multi-item 8-K: Items 7.01 and 9.01

Bally's Corp8-Kneutralmateriality 6/10

02-02-2026

Bally's Corp filed an 8-K on 2026-02-02 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), other events under Item 8.01, and financial statements/exhibits under Item 9.01. Specific details including the key position affected, whether it is an appointment or resignation, reasons for the change, timing, or any named executives are NOT_DISCLOSED. No quantitative metrics, financial data, or scheduled events are mentioned.

NEW JERSEY RESOURCES CORP8-Kneutralmateriality 7/10

02-02-2026

NEW JERSEY RESOURCES CORP filed an 8-K on February 02, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This multi-item filing discloses financial results but provides no specific revenue, earnings, guidance, or period-over-period metrics in the available information. No positive or negative financial changes are detailed, resulting in purely informational disclosure.

Newbridge Acquisition Ltd8-Kneutralmateriality 8/10

02-02-2026

Newbridge Acquisition Ltd filed an 8-K on 2026-02-02 disclosing entry into a Material Definitive Agreement under Item 1.01, likely related to a merger or acquisition, along with unregistered sales of equity securities (Item 3.02), amendments to articles of incorporation or bylaws and/or change in fiscal year (Item 5.03), other events (Item 8.01), and financial statements and exhibits (Item 9.01). No quantitative metrics, deal terms, parties beyond the filer, valuations, synergies, or performance comparisons (positive, negative, or flat) are disclosed. Critical details such as target company, deal structure, consideration, and timeline remain NOT_DISCLOSED.

RCI HOSPITALITY HOLDINGS, INC.8-Kbearishmateriality 10/10

02-02-2026

RCI Hospitality Holdings, Inc. filed Form 8-K on 2026-02-02 under Item 3.01 announcing a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Item 9.01 discloses Financial Statements and Exhibits. No specific reasons, timelines, financial impacts, or quantitative details are provided.

Esquire Financial Holdings, Inc.8-Kneutralmateriality 2/10

02-02-2026

Esquire Financial Holdings, Inc. filed an 8-K on February 2, 2026, disclosing under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the nature of the other events or the content of the exhibits are provided. This appears to be a voluntary informational filing with no quantified financial metrics or directional impacts disclosed.

CHEMUNG FINANCIAL CORP8-Kneutralmateriality 3/10

02-02-2026

Chemung Financial Corp filed an 8-K on 2026-02-02 under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits), indicating a voluntary release of material information with attached documents. The filing size is 8 MB, suggesting possible press releases, presentations, or financial exhibits. No specific transaction details, financial metrics, positive or negative changes, or events are disclosed in the provided information.

DALRADA FINANCIAL CORP8-K/Aneutralmateriality 8/10

02-02-2026

DALRADA FINANCIAL CORP filed an 8-K on February 2, 2026, reporting under Item 1.01 entry into a material definitive agreement and under Item 2.03 creation of a direct financial obligation or an obligation under an off-balance sheet arrangement. Item 9.01 includes financial statements and exhibits. No specific transaction details, dollar values, parties, terms, financial impacts, or quantitative metrics are disclosed in the provided filing summary.

Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 33 filings

Subscribe now Browse all digests

🇺🇸 More from United States

View all →

March 25, 2026

US Pre-Market SEC Filings Roundup — March 25, 2026

US Pre-Market SEC Filings Roundup

March 24, 2026

US Merger & Acquisition SEC Filings — March 24, 2026

US Merger & Acquisition SEC Filings

March 24, 2026

US Corporate Board Director Changes SEC Filings — March 24, 2026

US Corporate Board Director Changes SEC Filings

March 24, 2026

US Executive Officer Management Changes SEC — March 24, 2026

US Executive Officer Management Changes SEC

← All United States digests